Internal Reference Number: FOI_6430
Date Request Received: 13/01/2022 00:00:00
Date Request Replied To: 04/02/2022 00:00:00
This response was sent via: By Email
Request Summary: Rheumatology Meds
Request Category: Companies
Question Number 1: Could you provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
Answer To Question 1: Abatacept 44 Adalimumab Humira 26 Adalimumab Biosimilars 222 Apremilast 0 Baricitinib 72 Certolizumab 41 Etanercept Enbrel 10 Etanercept biosimilars 115 Filgotinib 14 Golimumab 24 Guselkumab 0 Infliximab Remicade 8 Infliximab biosimilars 26 Ixekizumab 27 Risankizumab 0 Rituximab Mabthera 0 Rituximab biosimilars 23 Sarilumab 1 Secukinumab 17 Tocilizumab 45 Tofacitinib 30 Upadacitinib 30 Ustekinumab 6 | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.